###begin article-title 0
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 61 67 61 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose
###end article-title 0
###begin p 1
Conceived and designed the experiments: MW PD. Performed the experiments: SB CB NE NS PW VR VK. Analyzed the data: FT RM. Contributed reagents/materials/analysis tools: WM AR MW PD. Wrote the paper: FT RM. Assembled clinical data: NE LH JL AR MW.
###end p 1
###begin p 2
###xml 160 161 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 168 170 168 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 731 737 719 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 795 797 771 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*2</italic>
###xml 799 801 775 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*3</italic>
###xml 853 859 829 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1012 1013 988 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1016 1019 992 995 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;78</sup>
###xml 1045 1051 1021 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 1084 1085 1060 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1088 1091 1064 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;31</sup>
###xml 1108 1114 1084 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1289 1295 1265 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 1297 1303 1273 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1389 1390 1365 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1399 1402 1375 1378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
###xml 1438 1444 1414 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 1512 1513 1488 1489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1502 1510 <span type="species:ncbi:9606">patients</span>
###xml 2112 2119 <span type="species:ncbi:9606">patient</span>
We report the first genome-wide association study (GWAS) whose sample size (1,053 Swedish subjects) is sufficiently powered to detect genome-wide significance (p<1.5x10-7) for polymorphisms that modestly alter therapeutic warfarin dose. The anticoagulant drug warfarin is widely prescribed for reducing the risk of stroke, thrombosis, pulmonary embolism, and coronary malfunction. However, Caucasians vary widely (20-fold) in the dose needed for therapeutic anticoagulation, and hence prescribed doses may be too low (risking serious illness) or too high (risking severe bleeding). Prior work established that approximately30% of the dose variance is explained by single nucleotide polymorphisms (SNPs) in the warfarin drug target VKORC1 and another approximately12% by two non-synonymous SNPs (*2, *3) in the cytochrome P450 warfarin-metabolizing gene CYP2C9. We initially tested each of 325,997 GWAS SNPs for association with warfarin dose by univariate regression and found the strongest statistical signals (p<10-78) at SNPs clustering near VKORC1 and the second lowest p-values (p<10-31) emanating from CYP2C9. No other SNPs approached genome-wide significance. To enhance detection of weaker effects, we conducted multiple regression adjusting for known influences on warfarin dose (VKORC1, CYP2C9, age, gender) and identified a single SNP (rs2108622) with genome-wide significance (p = 8.3x10-10) that alters protein coding of the CYP4F2 gene. We confirmed this result in 588 additional Swedish patients (p<0.0029) and, during our investigation, a second group provided independent confirmation from a scan of warfarin-metabolizing genes. We also thoroughly investigated copy number variations, haplotypes, and imputed SNPs, but found no additional highly significant warfarin associations. We present power analysis of our GWAS that is generalizable to other studies, and conclude we had 80% power to detect genome-wide significance for common causative variants or markers explaining at least 1.5% of dose variance. These GWAS results provide further impetus for conducting large-scale trials assessing patient benefit from genotype-based forecasting of warfarin dose.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 783 789 771 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 791 797 779 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 902 908 878 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 1222 1228 1198 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 1230 1236 1206 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1250 1256 1226 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 103 108 <span type="species:ncbi:9606">human</span>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
###xml 1130 1137 <span type="species:ncbi:9606">patient</span>
###xml 1194 1201 <span type="species:ncbi:9606">patient</span>
Recently, geneticists have begun assaying hundreds of thousands of genetic markers covering the entire human genome to systematically search for and identify genes that cause disease. We have extended this "genome-wide association study" (GWAS) method by assaying approximately326,000 markers in 1,053 Swedish patients in order to identify genes that alter response to the anticoagulant drug warfarin. Warfarin is widely prescribed to reduce blood clotting in order to protect high-risk patients from stroke, thrombosis, and heart attack. But patients vary widely (20-fold) in the warfarin dose needed for proper blood thinning, which means that initial doses in some patients are too high (risking severe bleeding) or too low (risking serious illness). Our GWAS detected two genes (VKORC1, CYP2C9) already known to cause approximately40% of the variability in warfarin dose and discovered a new gene (CYP4F2) contributing 1%-2% of the variability. Since our GWAS searched the entire genome, additional genes having a major influence on warfarin dose might not exist or be found in the near-term. Hence, clinical trials assessing patient benefit from individualized dose forecasting based on a patient's genetic makeup at VKORC1, CYP2C9 and possibly CYP4F2 could provide state-of-the-art clinical benchmarks for warfarin use during the foreseeable future.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 194 197 194 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Daly1">[1]</xref>
###xml 470 473 470 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Takahashi1">[2]</xref>
###xml 474 477 474 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Lindh1">[4]</xref>
###xml 563 570 <span type="species:ncbi:9606">patient</span>
Warfarin is the most widely prescribed anticoagulant for reducing thromboembolic events that often give rise to stroke, deep vein thrombosis, pulmonary embolism or serious coronary malfunctions [1]. A combination of genetic and non-genetic factors cause Caucasians to exhibit 20-fold interindividual variation in required warfarin dose needed to achieve the usual therapeutic level of anticoagulation as measured by the prothrombin international normalized ratio or INR [2]-[4]. Thus, in the absence of information (genotypic, clinical, etc.) for predicting each patient's required warfarin dose, initial prescribed doses may be too low (risking thrombosis) or too high (risking over-anticoagulation and severe bleeding). Warfarin's risk of serious side effects, narrow therapeutic range, and wide interindividual variation in warfarin dose have focused attention on the need to better predict dose in the initial stage(s) of treatment.
###end p 6
###begin p 7
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 235 238 223 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius2">[5]</xref>
###xml 239 242 227 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-DAndrea1">[6]</xref>
###xml 442 445 418 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius1">[3]</xref>
###xml 480 486 456 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 525 531 501 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 791 797 743 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 802 808 754 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 891 894 843 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Rettie1">[7]</xref>
###xml 976 979 928 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius1">[3]</xref>
###xml 301 309 <span type="species:ncbi:9606">patients</span>
###xml 393 400 <span type="species:ncbi:9606">patient</span>
We and others have shown that the warfarin drug target VKORC1 (vitamin K epoxide reductase complex, subunit 1) contains common polymorphisms that account for a major portion (approximately30%) of the variance in required warfarin dose [5],[6], and we have recently evaluated approximately1500 Swedish patients of the Warfarin Genetics (WARG) cohort in the largest study to date showing likely patient benefit from genetic forecasting of dose [3]. The study confirmed that SNPs in VKORC1 and in the warfarin-metabolizing gene CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) predict approximately40% of dose variance while non-genetic factors (age, sex, etc.) jointly account for another approximately15%. The robust and now widely replicated associations of warfarin dose with VKORC1 and CYP2C9 have provided one of the most successful applications of pharmacogenetics to date [7] and offer promise for genetic predication of required dose in a clinical setting [3].
###end p 7
###begin p 8
###xml 181 184 181 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius3">[8]</xref>
###xml 320 326 320 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 362 368 362 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 375 377 375 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*3</italic>
###xml 413 420 413 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t001">Table 1</xref>
###xml 424 427 424 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius3">[8]</xref>
###xml 463 469 463 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 475 477 475 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*2</italic>
###xml 575 577 575 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*2</italic>
###xml 708 715 708 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t003">Table 3</xref>
###xml 719 722 719 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius3">[8]</xref>
###xml 172 180 <span type="species:ncbi:9606">patients</span>
Knowledge of major predictors of warfarin dose also impacts the methodology for finding further dose-related genes. In early candidate gene work with a small sample of 201 patients [8], we noted that univariate regression (with tested SNP as the only dose predictor) could statistically detect warfarin association with VKORC1 and with one of two non-synonymous CYP2C9 SNPs (*3) known to influence warfarin dose (Table 1 in [8]). However, a second non-synonymous CYP2C9 SNP (*2) with known but weaker influence on warfarin dose was not detected by univariate regression, but *2 was statistically significant in multivariate regression adjusted for the other known genetic and non-genetic predictors of dose (Table 3 in [8]). These empirical results in a small warfarin sample provided a signpost underscoring the potential importance of multivariate regression for detecting weak effects in studies now searching for additional warfarin genes across the genome.
###end p 8
###begin title 9
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 135 136 135 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="nt101">a</xref>
Association (p-value) of SNPs tested by univariate regression or multiple regression with progressive addition of known dose predictorsa.
###end title 9
###begin p 10
Linear regression on warfarin dose was calculated for the 1,053 GWAS subjects.
###end p 10
###begin p 11
###xml 220 223 220 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wellcome1">[9]</xref>
###xml 396 402 396 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 402 406 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Cooper1">[10]</xref>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
A genome-wide association study (GWAS) enables a systematic search of the entire genome for genetic factors that cause any inherited trait. This method has successfully identified susceptibility loci for common diseases [9], and is beginning to be applied to pharmacogenomics. A recent warfarin GWAS in 181 patients did not detect other genetic factors with major effects on warfarin dose beyond VKORC1[10] but was underpowered for identifying loci with a moderate contribution. We have now genotyped 325,997 SNPs in 1053 patients of the WARG cohort and here report the first GWAS that is sufficiently powered to detect additional genetic factors that may only modestly influence warfarin dose.
###end p 11
###begin title 12
Results
###end title 12
###begin p 13
###xml 0 9 0 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000433-g001">Figure 1A</xref>
###xml 32 39 32 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t001">Table 1</xref>
###xml 209 215 209 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 217 226 217 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000433-g001">Figure 1A</xref>
###xml 272 273 272 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 282 285 282 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;78</sup>
###xml 317 323 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 330 333 330 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius1">[8]</xref>
###xml 423 429 423 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 527 528 527 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 528 529 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 643 647 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Rieder1">[11]</xref>
###xml 778 781 766 769 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;78</sup>
###xml 876 882 864 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 882 885 870 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius3">[8]</xref>
###xml 965 971 953 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1039 1041 1027 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*2</italic>
###xml 1043 1045 1031 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*3</italic>
###xml 1151 1154 1139 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius3">[8]</xref>
###xml 1268 1274 1256 1262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1302 1304 1290 1292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*2</italic>
###xml 1309 1311 1297 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*3</italic>
###xml 1421 1422 1409 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1422 1423 1410 1411 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1480 1482 1456 1458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*2</italic>
###xml 1487 1489 1463 1465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*3</italic>
###xml 1553 1554 1529 1530 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1554 1555 1530 1531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1573 1576 1549 1552 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;31</sup>
###xml 1610 1618 1586 1594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*2</italic>
###xml 1630 1631 1606 1607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1631 1632 1607 1608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1650 1653 1626 1629 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;13</sup>
###xml 1659 1667 1635 1643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*3</italic>
###xml 1679 1680 1655 1656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1680 1681 1656 1657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1699 1702 1675 1678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;17</sup>
###xml 1705 1714 1681 1690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000433-g001">Figure 1A</xref>
###xml 1782 1784 1758 1760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*2</italic>
###xml 1789 1791 1765 1767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*3</italic>
Figure 1A and the first line of Table 1 summarize results of testing 325,997 GWAS SNPs for association with warfarin dose by univariate regression. The strongest associations were at multiple SNPs in and near VKORC1 (Figure 1A) with the lowest p-value given by rs9923231 (P = 5.4x10-78). In prior fine-mapping of the VKORC1 locus [8], we identified rs9923231 as one of three SNPs located in introns or immediately flanking VKORC1 that exhibit almost perfectly concordant genotypes yielding pairwise linkage disequilibrium (LD) r2approximately1 and which define the warfarin-sensitive A-T-T haplotype at rs9923231-rs9934438-rs2359612 (see also [11]). These highly concordant SNPs were the best predictors of warfarin dose in our previous study and in this GWAS analysis (p<5.4x10-78) and completely accounted for the dose variance explained by all other fine-mapping SNPs near VKORC1[8]. The group of SNPs with the second lowest univariate p-values clustered around CYP2C9 which contains two non-synonymous exonic SNPs whose minor alleles (*2, *3) impair warfarin metabolism and are well known to be associated with warfarin dose. In our previous work [8], we discovered an unusual SNP (rs4917639) whose minor allele is almost perfectly associated with the "composite" CYP2C9 allele formed by combining *2 and *3 into a single allele. Indeed, the GWAS results (1053 subjects) confirmed that LD is nearly perfect (pairwise r2approximately1.0) between rs4917639 and the composite of *2 and *3. Thus, the highly significant univariate result for rs4917639 (R2 = 0.121, p<3.1x10-31) reflects the combined effect of CYP2C9*2 rs1799853 (R2 = 0.038, p<8.8x10-13) and CYP2C9*3 rs1057910 (R2 = 0.080, p<4.5x10-17). Figure 1A therefore indicates p-values for this composite SNP as well as for *2 and *3.
###end p 13
###begin title 14
P-values for each GWAS SNP tested for association with warfarin dose.
###end title 14
###begin p 15
###xml 278 280 278 280 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 438 444 438 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 452 453 452 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 462 465 462 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;78</sup>
###xml 518 524 518 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 526 527 526 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 536 539 536 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;17</sup>
###xml 559 565 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*3 SNP</italic>
###xml 577 578 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 587 590 587 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;13</sup>
###xml 610 616 610 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*2 SNP</italic>
###xml 628 629 628 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 638 641 638 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;31</sup>
###xml 646 650 646 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*2*3</italic>
###xml 742 748 742 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 753 759 753 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 861 867 861 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 874 875 874 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 884 887 884 887 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
Horizontal axis shows SNP location and vertical axis is -log10(p-value) for each SNP tested by univariate regression (A) or multivariate regression (B). Red dots and red lettering show SNPs and implicated genes with p-values beyond the genome-wide significance threshold (1.5x10-7) which is denoted by a horizontal line. (A) Univariate regression shows genome-wide significant association to SNPs clustering near the warfarin drug target VKORC1 (e.g., P = 5.4x10-78, rs9923231) and near the warfarin-metabolizing gene CYP2C9 (P = 4.5x10-17 for non-synonymous *3 SNP rs1057910, P = 8.8x10-13 for non-synonymous *2 SNP rs1799853, P = 3.1x10-31 for *2*3 "composite" SNP rs4917639). (B) Multivariate regression adjusting for the contributions of VKORC1 and CYP2C9 had greater power than univariate regression and detected genome-wide significant association to the CYP4F2 gene (P = 8.3x10-10, non-synonymous SNP rs2108622).
###end p 15
###begin p 16
###xml 0 9 0 9 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000433-g001">Figure 1B</xref>
###xml 14 21 14 21 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t001">Table 1</xref>
###xml 295 297 295 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 349 355 349 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 605 611 593 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 616 622 604 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 742 750 730 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*2</italic>
###xml 795 797 783 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*2</italic>
###xml 837 840 825 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius3">[8]</xref>
###xml 857 864 845 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t001">Table 1</xref>
###xml 883 889 871 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 939 941 927 929 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 1111 1114 1099 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
###xml 1180 1182 1168 1170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 1189 1195 1177 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 1386 1389 1374 1377 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
###xml 1428 1435 1416 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t002">Table 2</xref>
###xml 1596 1602 1584 1590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 1654 1658 1642 1646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Caldwell1">[12]</xref>
###xml 707 715 <span type="species:ncbi:9606">patients</span>
###xml 1298 1306 <span type="species:ncbi:9606">patients</span>
Figure 1B and Table 1 (lines 2 to 5) show the results of multivariate regression analysis in which individual SNPs were tested for association with warfarin dose after adjustment for established genetic and non-genetic predictors of dose. The only SNP reaching genome-wide significance (p<1.5x10-7) was a non-synonymous SNP (rs2108622) in exon 2 of CYP4F2 (cytochrome P450, family 4, subfamily F, polypeptide 2) introducing a Val to Met amino acid change at position 433 (V433M). SNP rs2108622 predicts additional dose variance (approximately1.1%) that is independent of the variance already explained by VKORC1 and CYP2C9. As noted in the Introduction, our early studies with a small sample of 201 Swedish patients failed to detect the weak CYP2C9*2 effect on dose by univariate regression but *2 was significant in multiple regression [8]. The results in Table 1 with rs2108622 of CYP4F2 show the same phenomenon with a p-value of 1.6x10-5 in univariate regression (line 1) but progressively lower p-values as known predictors are added to the multivariate model so that for the full model a p-value of 8.3x10-10 is achieved which is far below genome-wide significance (p<1.5x10-7). The CYP4F2 association was further confirmed by testing an independent replication panel of 588 Swedish warfarin patients who gave a multivariate p-value of 0.0029 and a total overall p-value of 3.3x10-10 when combined with the GWAS subjects (Table 2). During preparation of this paper, a candidate gene study of drug-metabolizing and transporter genes independently discovered the association of rs2108622 and CYP4F2 with warfarin dose, providing further confirmation [12].
###end p 16
###begin title 17
Multiple regression analysis of warfarin dose in the GWAS, replication and combined panels.
###end title 17
###begin p 18
In parenthesis are major/minor allele, and minor allele frequency.
###end p 18
###begin p 19
###xml 141 142 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 142 143 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 149 150 149 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Effect of individual predictor on dose is indicated by regression coefficient and 95% confidence interval, proportion of explained variance (R2) and P-value.
###end p 19
###begin p 20
Association in same direction as GWAS was assessed by a one-tailed test.
###end p 20
###begin p 21
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 355 364 355 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000433.s001">Figure S1</xref>
###xml 584 590 584 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 592 598 592 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 602 608 602 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 807 828 807 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 960 962 960 962 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 1005 1007 993 995 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 843 846 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 938 941 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
To increase the power of our multivariate regression model and possibly detect additional weak effects, we added CYP4F2 (rs2108622) to the model as a predictor and conducted further analyses. First, we retested the GWAS SNPs, but no new SNPs reached genome-wide significance and there was also no apparent excess of SNPs at lower significance thresholds (Figure S1). We also tested warfarin association with haplotypes and with ungenotyped SNPs imputed at 2.2 million HapMap SNPs, but no haplotype or imputed SNP approached genome-wide significance in a genomic region not containing VKORC1, CYP2C9 or CYP4F2. To explore whether copy number variations (CNVs) detectable by the HumanCNV370 array might influence warfarin dose, we used rigorous quality control and retained 879 samples calling 2530 CNVs (see Materials and Methods). None of the CNV loci were significantly associated with dose after correction for multiple testing (lowest CNV p-value was 1.1x10-4 which exceeds 0.05/2530approximately2.0x10-5). We note that probe density in many of the detected CNVs is not optimal for conducting association analyses and these results should therefore be viewed as preliminary.
###end p 21
###begin p 22
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 149 151 149 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 418 426 418 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000433.s003">Table S1</xref>
###xml 653 675 653 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1, CYP2C9, CYP4F2</italic>
###xml 814 822 814 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000433.s004">Table S2</xref>
###xml 247 255 <span type="species:ncbi:9606">patients</span>
Finally, after excluding SNPs near VKORC1, CYP2C9 and CYP4F2, we identified 40 other loci containing one or more GWAS SNPs with p-values below 2.0x10-4 and we genotyped 40 SNPs representing these loci in a follow-up sample of 588 Swedish warfarin patients. However none of the 40 loci replicated for association with warfarin dose, the lowest p-value being 0.04 which is not significant after correction for 40 tests (Table S1). Having not found evidence for any additional genetic modulators of dose, we examined the entire data set (GWAS plus followup samples) for evidence of statistical interaction between pairs of the established dose predictors (VKORC1, CYP2C9, CYP4F2, age, sex). None of the pairs exhibited statistically significant interaction after p-values were corrected for the 15 interaction tests (Table S2).
###end p 22
###begin p 23
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 129 135 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 162 165 162 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius1">[3]</xref>
###xml 704 725 704 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 829 831 829 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 863 869 863 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 901 903 901 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;9</sup>
###xml 968 976 968 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*3</italic>
###xml 986 988 986 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 991 999 991 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*2</italic>
###xml 1031 1035 1031 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*2*3</italic>
###xml 1061 1070 1061 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000433.s002">Figure S2</xref>
###xml 1264 1270 1264 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 1282 1283 1282 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1292 1295 1292 1295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;11</sup>
###xml 1301 1309 1301 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*3</italic>
###xml 1311 1312 1311 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1321 1323 1321 1323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;9</sup>
###xml 1325 1328 1325 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius1">[3]</xref>
###xml 1577 1583 1577 1583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 1588 1596 1588 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*3</italic>
###xml 1644 1645 1644 1645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1653 1661 1653 1661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000433.s005">Table S3</xref>
###xml 397 404 <span type="species:ncbi:9606">patient</span>
###xml 652 660 <span type="species:ncbi:9606">patients</span>
We also performed a GWAS for a secondary trait ("over-anticoagulation") which we previously found was associated with VKORC1 and CYP2C9 in a candidate gene study [3]. By titrating warfarin dose, physicians attempt to achieve a target level of anticoagulation determined by a reading of 2.0 to 3.0 for the prothrombin international normalized ratio (INR), which is the ratio of time required for a patient's blood to coagulate relative to that of a reference sample. However over-anticoagulation (defined as an INR above 4.0) sometimes occurs and, using Cox regression, our GWAS tested for SNP association with the occurrence of over-anticoagulation in patients during the first 5 weeks of treatment (see Materials and Methods: Association testing of SNPs and haplotypes). We observed genome-wide significant association (p<1.5x10-7) at several SNPs in and around VKORC1 including rs9923231 (P = 8.9x10-9), but no other SNPs achieved genome-wide significance including CYP2C9*3 (p<4.0x10-5), CYP2C9*2 (p = 0.93), or the "composite" *2*3 SNP rs4917639 (p<0.007) (Figure S2). However we note that our previous candidate gene study evaluated a larger sample set (1496 WARG subjects) which yielded genome-wide significant association with over-anticoagulation for both VKORC1 rs9923231 (P = 5.7x10-11) and CYP2C9*3 (P = 1.5x10-9) [3]. To explore whether these SNPs might cause over-anticoagulation independent of altering the required (i.e., administered) warfarin dose, we added required dose to the Cox regression model as a predictor of over-anticoagulation, and found that both VKORC1 and CYP2C9*3 have a significant effect independent of dose (P<0.05) (Table S3).
###end p 23
###begin title 24
Discussion
###end title 24
###begin p 25
###xml 201 210 201 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000433-g001">Figure 1A</xref>
###xml 271 274 271 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;78</sup>
###xml 280 283 280 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;13</sup>
###xml 305 311 305 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 316 322 316 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 538 547 514 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000433-g001">Figure 1B</xref>
###xml 603 606 579 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;10</sup>
###xml 610 616 586 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 786 793 762 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t001">Table 1</xref>
###xml 838 844 814 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 854 856 830 832 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 984 990 960 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 1087 1091 1063 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Caldwell1">[12]</xref>
###xml 1170 1176 1146 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 1187 1191 1163 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Cooper1">[10]</xref>
###xml 1198 1204 1174 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 1527 1529 1491 1493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">do</italic>
###xml 1666 1670 1630 1634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Haley1">[13]</xref>
###xml 1671 1675 1635 1639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Jansen1">[14]</xref>
We conducted the first GWAS sufficiently powered to detect DNA variants with a modest influence on the warfarin dose needed to achieve therapeutic anticoagulation. In univariate analysis of GWAS SNPs (Figure 1A), we identified extremely strong association signals (p = 10-78 to 10-13) at SNPs in and near VKORC1 and CYP2C9, two genes already known to explain approximately30% and approximately12% of warfarin dose variance, respectively. By applying multivariate regression adjusting for known genetic and non-genetic predictors of dose (Figure 1B), we also detected genome-wide significance of p<8.3x10-10 at CYP4F2 (rs2108622) that accounted for approximately 1.5% of dose variance. The increased power of multivariate regression to detect this modest effect is nicely illustrated in Table 1 which shows a higher univariate p-value for CYP4F2 (p<1.6x10-5) but progressively lower multivariate p-values as known predictors of dose are added to the regression model. We confirmed the CYP4F2 association in a second large sample set and the association was also reported by another group [12] during preparation of our work, thus fully establishing the genuine effect of CYP4F2 (see also [10] where CYP4F2 explained approximately1% dose variance with nominal p<0.043 significance). Although multivariate regression has not been widely used to increase power in other GWAS analyses because known genetic variants usually explain little phenotypic variance, the potential for power increase is perhaps obvious if known predictors do explain substantial variance. Thus multiple regression has, for example, been previously advocated for linkage analyses of line crosses [13],[14].
###end p 25
###begin p 26
###xml 99 120 99 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 225 232 225 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t003">Table 3</xref>
###xml 307 309 307 309 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 335 341 335 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 356 364 356 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*3</italic>
###xml 372 380 372 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*2</italic>
###xml 425 431 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 477 483 465 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
To estimate the multivariate regression power of our GWAS (1053 subjects), we used Equation 1 (see Materials and Methods) to calculate power to detect SNPs explaining specific magnitudes of variance () for warfarin dose (see Table 3). The table shows that power to achieve genome-wide significance (p<1.5x10-7) is essentially 100% for VKORC1 rs9923231 (), CYP2C9*3 () and CYP2C9*2 (), but power falls to approximately48% for CYP4F2 rs2108622 (). The table also shows that when CYP4F2 is added to the multivariate model, a SNP accounting for 1.5% or 1.0% of the dose variance would have approximately82% or approximately41% power of being detected, respectively. Therefore we estimate that our GWAS had at least 80% power to detect warfarin-associated variants explaining at least 1.5% of the dose variance but 40% or less power to detect genome-wide significance if a variant accounts for 1% or less dose variance.
###end p 26
###begin title 27
###xml 88 89 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="nt105">a</xref>
Power to detect a dose-altering SNP as a function of its contribution to dose variance (R2) and adjustment by other predictors in the multiple regression modela.
###end title 27
###begin p 28
Power calculations assumed a sample size of 1,053 subjects and significance level of 1.5E-7 as employed in our GWAS.
###end p 28
###begin p 29
###xml 270 277 270 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t003">Table 3</xref>
###xml 357 365 357 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*2</italic>
###xml 370 372 370 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*3</italic>
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Stubbins1">[15]</xref>
###xml 428 432 428 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Aithal1">[16]</xref>
###xml 459 465 459 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 790 791 790 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 791 792 791 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 828 849 828 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 982 1003 982 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 1206 1210 1206 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Pritchard1">[17]</xref>
###xml 1284 1294 1284 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">undetected</italic>
###xml 1531 1532 1507 1508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1532 1533 1508 1509 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1589 1590 1541 1542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1590 1591 1542 1543 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1848 1855 1800 1807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t003">Table 3</xref>
###xml 1990 1991 1940 1941 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1991 1992 1941 1942 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 2019 2020 1969 1970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 2020 2021 1970 1971 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 2029 2030 1979 1980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 2030 2031 1980 1981 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 2105 2109 2031 2035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Bhangale1">[18]</xref>
###xml 2114 2115 2040 2041 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 2115 2116 2041 2042 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 2172 2176 2086 2090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Evans1">[19]</xref>
However it is important to emphasize that these power estimates assume that the dose-altering DNA variant is genotyped and tested directly or is indirectly detected through a marker in sufficiently high LD to the dose variant that the marker's  magnitude is detectable (Table 3). The assumption of directly testing the dose-altering variant is accurate for CYP2C9*2 and *3 which are each known to alter warfarin metabolism [15],[16] and is likely correct for CYP4F2 rs2108622 which, like *2 and *3, changes protein coding sequence. However, to explore whether other dose-altering variants might be undetected due to insufficient LD with genotyped GWAS SNPs, we determined the relationship between the variance observed at a marker () and at the causative variant () assuming pairwise LD of r2 between the two polymorphisms (see Materials and Methods: How Much Does Linkage Disequilibrium Attenuate Association with a Quantitative Trait?). The relationship is given by Equation 3 in Materials and Methods () which is analogous to Pritchard and Prezworski's relationship () for the number of cases () providing equal power in a case-control study that tests either the disease-causing SNP or a nearby marker [17]. To use the equation  to estimate  magnitudes for variants that might be undetected by our GWAS, we note that approximately90% of the GWAS SNPs had a minor allele frequency (MAF) above 10% in our warfarin subjects implying that a "rare" dose-altering variant (MAFapproximately1%-5%) would be covered at a likely maximum r2 of only approximately0.1 to approximately0.5. This low r2 coverage implies that rare variants could have  values (0.05 to 0.02) easily detected by regression testing of the variant itself, but unlikely to be detected through a GWAS marker since maximum  values could drop to 0.01 or much lower (see Equation 3 and Table 3). By contrast, "common" SNPs (MAF>/=5%), which might also be dose variants, are covered by GWAS SNPs of this study at reasonably high r2 values in most instances (r2>0.8 or r2>0.5 for approximately60% or approximately80% respectively of common SNPs [18] and r2>0.9 for approximately90% of non-synonymous common SNPs [19] in HapMap Caucasians). We therefore conclude that our GWAS probably detected most common SNP variants explaining 1.5% or more of the warfarin dose variance, but may have failed to detect rarer variants that could individually explain up to 5% of dose variance. We further note that the HumanCNV370 array used in this study does not have the required marker complement to undertake a comprehensive GWAS of common CNVs.
###end p 29
###begin p 30
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 95 101 95 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Caldwell1">[12]</xref>
###xml 269 275 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 556 562 556 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 674 680 662 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 857 863 845 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 926 930 914 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Scott1">[20]</xref>
As noted in the Introduction, the widely replicated warfarin dose associations with VKORC1 and CYP2C9 represent one of the most successful applications of pharmacogenetics to date. Our study together with that of Caldwell et al. [12] now also clearly demonstrates that CYP4F2 (rs2108622) is a third gene that influences warfarin dose, but our GWAS and statistical analysis also implies that additional common SNP variants that influence dose may not exist in Caucasian populations. However, Caucasians might carry common variants with effects smaller than CYP4F2 or rare variants whose effects are substantially larger than the approximately1% of dose variance explained by CYP4F2. Furthermore, other unidentified genes may influence warfarin dose in other ethnicities such as Asians or Africans, and some rare dose-altering variants in known genes such as VKORC1 may exist in only a subset of populations of European descent [20]. Hence, future research could address ethnic differences in the genetic variants that influence warfarin dose as well as subtle intra-ethnic differences and admixture that may exist in European or other populations.
###end p 30
###begin p 31
###xml 18 21 18 21 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius1">[3]</xref>
###xml 145 151 145 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 371 377 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 565 569 565 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Anderson1">[21]</xref>
###xml 570 574 570 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Caraco1">[22]</xref>
###xml 609 613 609 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Lenzini1">[23]</xref>
###xml 614 618 614 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Hillman1">[27]</xref>
###xml 764 770 764 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 1009 1015 1009 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 1020 1026 1020 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1055 1061 1055 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 124 131 <span type="species:ncbi:9606">patient</span>
###xml 353 361 <span type="species:ncbi:9606">patients</span>
###xml 502 509 <span type="species:ncbi:9606">patient</span>
###xml 962 969 <span type="species:ncbi:9606">patient</span>
In a recent study [3], we highlighted the potential benefit of pre-treatment forecasting of required warfarin dose based on patient genotypes at VKORC1 and CYP2C9 together with non-genetic predictors of dose. Indeed, in August 2007, the US Food and Drug Administration (FDA) updated warfarin labeling to recommend initiating lower warfarin dose in some patients based on VKORC1 and CYP2C9 genotypes. However this recommendation is not a requirement due to a lack of large trials demonstrating warfarin patient benefit from dose forecasting (though two small trials [21],[22] do support such benefit; see also [23]-[27] for reviews and other trials). The results of our GWAS provide further impetus for conducting large-scale dose-forecasting trials by identifying CYP4F2 as a third genetic predictor of dose and also by showing that additional major genetic predictors may not exist in Caucasians or may not emerge in the near-term. Hence, large-scale trials of patient benefit from dose forecasting based on VKORC1 and CYP2C9 (with possible inclusion of CYP4F2 as a minor predictor) are likely to provide state-of-the-art clinical benchmarks for warfarin use during the foreseeable future.
###end p 31
###begin title 32
Materials and Methods
###end title 32
###begin title 33
Subjects and Clinical Data
###end title 33
###begin p 34
###xml 75 78 75 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius1">[3]</xref>
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Lindh2">[28]</xref>
###xml 625 628 625 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius1">[3]</xref>
###xml 1533 1536 1533 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius1">[3]</xref>
###xml 1537 1540 1537 1540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Lindh1">[4]</xref>
###xml 1541 1545 1541 1545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Lindh2">[28]</xref>
###xml 1546 1550 1546 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Lindh3">[29]</xref>
###xml 1588 1591 1588 1591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius3">[8]</xref>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 277 284 <span type="species:ncbi:9606">patient</span>
###xml 539 546 <span type="species:ncbi:9606">patient</span>
###xml 683 690 <span type="species:ncbi:9606">patient</span>
The study subjects were 1053 Swedish patients collected for the WARG study [3] (). This is a multi-centre study of warfarin bleeding complications and response to warfarin treatment [28]. Anticoagulant response is measured by INR, which is the ratio of the time required for a patient's blood to coagulate relative to that of a reference sample. By titrating warfarin dose, physicians aim for a therapeutic INR reading between 2.0 and 3.0; thus the primary quantitative outcome for the GWAS was the mean warfarin dose (mg/week) given to a patient during a minimum series of three consecutive INR measurements between 2 and 3 [3]. As a secondary GWAS outcome, we also catalogued each patient for the occurrence or non-occurrence of "over-anticoagulation" during the first 5 weeks of treatment (defined as an INR reading above 4.0) and tested for genetic association which adjusted for the treatment day (1 to 35) of the over-anticoagulation event (see "Association testing" below). The clinical data collected by the WARG protocol included gender and age since each is a known non-genetic predictor of warfarin dose but did not include bodyweight and dietary information (e.g. vitamin K intake). Regression analysis of prescribed medication which can potentiate or inhibit warfarin action was not a statistically significant predictor of warfarin dose in the 1053 WARG GWAS subjects and hence was not included as a predictor variable in the multivariate regression analyses. The WARG study samples were previously described elsewhere [3],[4],[28],[29] as were the Uppsala followup samples [8]. The WARG and Uppsala studies received ethical approval from the Ethics Committee of the Karolinska Institute and the Research Ethics Committee at Uppsala University, respectively.
###end p 34
###begin title 35
Genotyping of SNPs and Sample Quality Control
###end title 35
###begin p 36
###xml 37 40 37 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius1">[3]</xref>
###xml 422 424 406 408 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1189 1195 1161 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 1212 1220 1184 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*2</italic>
###xml 195 198 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1008 1016 <span type="species:ncbi:9606">patients</span>
From approximately 1500 WARG samples [3] examined for non-degradation and appropriate concentration of DNA (approximately50 ng/microl), we randomly selected 1208 subjects for genotyping SNPs and CNV probes using the HumanCNV370 BeadChip array (Illumina). We excluded SNPs with MAF below 1%, call rate below 95%, or if call rate fell below 99% when MAF was below 5%. SNPs that departed from Hardy-Weinberg equilibrium (P<10-6) were also excluded. Subjects with genotyping call rate below 95% were also eliminated. Using iPLEX (Sequenom), subject identity (and associated phenotypic data) was cross-checked by genotyping four gender markers and 47 SNPs also carried on the HumanCNV370 array, enabling us to exclude approximately136 misidentified subjects. Sample quality (contamination) was further assessed by plotting each subject's genome-wide heterozygosity and eliminating outliers (with heterozygosity above or below the range of 0.312-0.372). After these quality control steps, a total of 1053 warfarin patients and 325,997 GWAS SNPs were retained for analysis. The GWAS SNPs included two SNPs not on the HumanCNV370 array but which are highly predictive of warfarin dose [rs9923231 (VKORC1) and rs1799853 (CYP2C9*2)] which we genotyped by TaqMan assay (Applied Biosystems).
###end p 36
###begin title 37
###xml 9 12 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Defining CNV Regions
###end title 37
###begin p 38
###xml 250 254 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Peiffer1">[30]</xref>
###xml 347 351 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Marioni1">[31]</xref>
###xml 451 455 439 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Olshen1">[32]</xref>
###xml 135 140 <span type="species:ncbi:9606">Human</span>
###xml 781 784 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 853 856 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Although we retained 325,997 GWAS SNPs for association testing of SNPs, it should be noted that all approximately370,000 probes on the Human CNV370 array were used to define CNVs. Log R ratio values of probes were output from the BeadStudio software [30]. A loess correction was applied to each sample to remove local correlations or genomic wave [31]. The resultant genomic copy number profiles were then segmented using Circular Binary Segmentation [32]. Some samples displayed abnormally high numbers of segments indicating problems in DNA quantity or quality or hybridization. Samples were removed until the number of segments across all samples was approximately normal. Using this technique, 143 (14%) of samples were flagged as problematic. These samples were excluded when CNV regions were defined but included for association testing. Putative CNV were defined from segments by applying a threshold on the segment log R ratio. This threshold was asymmetric allowing for a differing response for deletions and duplications. The central peak of the segment log R ratio distribution was fitted and the threshold values obtained by taking values at +/-5 standard deviations from the centre.
###end p 38
###begin p 39
###xml 422 426 422 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Iafrate1">[33]</xref>
###xml 63 66 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 139 142 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 235 238 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 479 482 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 556 559 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
In order to define regions for association testing, merging of CNV across samples was performed. This was achieved by merging two putative CNV into a region if there was greater than 40% reciprocal overlap. This procedure defined 2530 CNV regions in total. Of these, most were singletons (54%) or low frequency, <3% (93%), while 820 (70%) of the non-singleton regions overlapped CNVs from the Database of Genomic Variants [33]. We tested all 2530 CNVs for association, because a CNV discovered as a "singleton" might well include multiple copies of a rare CNV allele in the study samples.
###end p 39
###begin title 40
Association Testing of SNPs and Haplotypes
###end title 40
###begin p 41
###xml 121 124 121 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius3">[8]</xref>
###xml 208 212 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Purcell1">[34]</xref>
###xml 408 412 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Browning1">[35]</xref>
###xml 465 469 453 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Frazer1">[36]</xref>
At each SNP, genotypes were coded 0, 1 or 2 and the SNP was tested for association with the square root of warfarin dose [8] by either univariate or multivariate linear regression analysis conducted in PLINK [34] () or in R software (). We used the same regression analysis to test association with all HapMap SNPs not on the HumanCNV370 array by imputing approximately2.2 million SNPs using Beagle software [35] trained from genotypes of the 60 HapMap CEU parents [36]. We excluded SNPs whose imputed MAF was below 5% or differed by more than 5% with MAF of the CEU parents.
###end p 41
###begin p 42
###xml 229 235 229 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 718 726 <span type="species:ncbi:9606">patients</span>
We also tested haplotypes for association with warfarin dose by two approaches: (1) each subject's warfarin dose residual (difference between observed and predicted dose based on the full multivariate regression model containing CYP4F2) was considered a quantitative trait value and tested for association with haplotypes defined across the genome in sliding windows of 2, 3 or 4 consecutive SNPs as implemented by PLINK software; (2) by scanning GWAS genotypes, Beagle software groups genetically related haplotypes into clusters which it then resolves into diallelic (SNP-like) "pseudo-markers" optimized for detecting phenotypic association. To test haplotypes, we evaluated the pseudo-marker genotypes of warfarin patients at 1.97 million pseudo-markers covering the genome by testing each pseudo-marker in the same multivariate regression framework used to test individual SNPs (as described in the preceding paragraph).
###end p 42
###begin p 43
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 147 153 147 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
We tested for statistical interaction in modulating warfarin dose for each pair of established dose predictors (VKORC1 rs9923231, CYP2C9*2 and *3, CYP4F2 rs2108622, Age, Sex) using multivariate regression and R software as described above. An interaction term formed by multiplying the pair of predictor variables was added to the multivariate regression equation which contained only main effects of the 6 predictors, and standard ANOVA compared this main-effect model with the enhanced interaction model by testing for a statistically significant increase in explained dose variance. Interaction test p-values were considered statistically significant if below the Bonferroni cutpoint determined by correcting for the 15 interaction tests (i.e. p<0.0033approximately0.05/15).
###end p 43
###begin p 44
To test for association with over-anticoagulation (INR>4.0) during treatment days 1-35, we performed Cox proportional hazard regression on survival time (day of over-anticoagulation) using the survival library of R software. The GWAS data set of 1053 WARG subjects contained 215 subjects whose INR exceeded 4.0 during days 1-35 while the entire dataset of 1489 WARG subjects contained 312 such subjects.
###end p 44
###begin title 45
Association Testing of CNVs
###end title 45
###begin p 46
###xml 1377 1381 1377 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Barnes1">[37]</xref>
###xml 9 12 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 160 163 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 263 266 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 488 491 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 864 867 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1082 1085 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 1256 1259 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
For each CNV locus, association was tested with square root of warfarin dose by multivariate regression analysis in which subject copy number intensity was the CNV predictor of dose. This analysis differs from association testing with SNP genotypes since the two CNV alleles on homologous chromosomes generate one copy number intensity rather than a separate allele for each chromosome. As a QC strategy, we determined each subject's rank in the dataset for copy number intensity at each CNV on chromosome 17. This enabled us to differentiate the majority of subjects (whose individual distribution of ranks were approximately random and uniform) from 174 obvious outliers due to poor quality DNA (whose ranking distributions were "U-shaped" since their intensities strongly clustered at both high and low ranks). These 174 subjects were excluded from the primary CNV association analysis (with further confirmation of lower quality DNA for these subjects being their rough correspondence to the subjects with lower (<99%) SNP call rates). However, we also crosschecked the primary CNV analysis by conducting association testing on the dataset without excluding the 174 subjects and found no statistically significant association with warfarin dose at any CNV whether the dataset excluded or included the subjects. Association testing of the CNVs was executed using R software [37].
###end p 46
###begin title 47
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
Replication of CYP4F2
###end title 47
###begin p 48
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 135 138 135 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius1">[3]</xref>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Wadelius4">[38]</xref>
###xml 177 184 177 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t002">Table 2</xref>
###xml 298 306 298 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000433.s006">Table S4</xref>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
For the replication of CYP4F2 rs2108622, we genotyped a panel of 588 warfarin patients consisting of 410 subjects from the WARG cohort [3] and 178 from the Uppsala cohort [38]. Table 2 shows regression on this pooled sample of 588 subjects. Separate results for each of the two panels are given in Table S4.
###end p 48
###begin title 49
Follow-Up of Moderately Significant SNPs
###end title 49
###begin p 50
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 398 404 398 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 379 387 <span type="species:ncbi:9606">patients</span>
To possibly identify SNPs with genuine but weak associations to warfarin dose, we excluded VKORC1, CYP2C9, CYP4F2 and identified 40 other GWAS loci for follow-up genotyping exhibiting multivariate regression p-values below 0.0002, and selected 40 SNPs representing these loci for genotyping. Only genotyped (not imputed) SNPs were chosen for follow-up. We genotyped the same 558 patients as in the CYP4F2 replication using the iPLEX MassARRAY.
###end p 50
###begin title 51
Power Calculation
###end title 51
###begin p 52
###xml 53 54 53 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 147 148 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 149 153 149 153 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">test</sub>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>test</sub></italic>
###xml 239 240 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 240 241 240 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 241 244 241 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">knw</sub>
###xml 241 244 241 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><sub>knw</sub></italic>
###xml 338 340 334 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F&#8242;</italic>
###xml 344 345 340 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 349 354 345 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#952;</italic>
###xml 354 355 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 400 401 392 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 423 424 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 475 480 467 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#952;</italic>
###xml 480 481 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 500 504 488 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Stuart1">[39]</xref>
###xml 521 525 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Knight1">[40]</xref>
###xml 546 547 534 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</italic>
###xml 614 615 598 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 619 620 603 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 666 667 650 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 710 711 694 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
Suppose multiple regression analysis is conducted in N total samples by testing a SNP with coefficient of determination (i.e., explained variance) R2test after adjustment for known predictors whose total of coefficient of determination is R2knw. The probability (power) to detect the tested SNP at a significance level alpha equals:where F'(1, N-2, theta2) is the probability density function for an F distribution with 1, N-2 degrees of freedom and non-centrality parameter theta2 (Section 28.28 in [39], Example 8.4 in [40]). Here the constant c satisfies the equation:where alpha is the significance level, and F(1, N-2) is the probability density function for a F-distribution of degree of freedom one and N-2.
###end p 52
###begin title 53
How Much Does Linkage Disequilbrium (LD) Attenuate Association with a Quantitative Trait?
###end title 53
###begin p 54
###xml 540 544 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Pritchard1">[17]</xref>
###xml 665 666 665 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 666 667 666 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Association with a quantitative trait (QT) becomes weaker for a marker SNP in LD with a SNP that alters the QT, and hence the association becomes more difficult to detect at the marker than at the QT-altering SNP. Here we quantify the LD attenuation for a QT when testing for association by linear regression (which includes the Cochran-Armitage trend test for dichotomous traits), and we obtain a result analogous to the LD attenuation for the Pearson Chi-square test for allelic association to dichotomous traits as in cases and controls [17]. If a causative QT-altering SNP has a coefficient of determination (i.e., explained variance)  and is in pairwise LD of r2 with a marker SNP, then the coefficient of determination for the marker SNP () is approximated by:
###end p 54
###begin p 55
###xml 101 102 101 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
In other words, when testing a marker, the proportion of explained variance decreases by a factor of r2.
###end p 55
###begin p 56
###xml 84 85 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</italic>
###xml 97 98 97 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</italic>
###xml 105 106 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 355 356 355 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</italic>
###xml 360 361 360 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 367 368 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</italic>
To begin the proof of Equation 3, let the QT be represented by the random variable "q", and let "m" and "x" be SNP genotypes (coded 0, 1, or 2) representing the marker and causative (QT-altering) SNP, respectively. The coefficients of determination  are equal to the square of two correlation coefficients (denoted by "Corr") measuring the correlation of m or x with q:
###end p 56
###begin p 57
###xml 35 44 35 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">genotypes</italic>
Also note that correlation between genotypes at the marker and causative SNP is given by another correlation coefficient:
###end p 57
###begin p 58
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">partial</italic>
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</italic>
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</italic>
###xml 84 85 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</italic>
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Sokal1">[41]</xref>
It is well known that the partial correlation coefficient of m and q conditioned on x is (equation 16.20, p. 649 in [41]):
###end p 58
###begin p 59
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</italic>
###xml 75 76 75 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</italic>
###xml 109 110 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</italic>
However, conditional on genotype at the causative SNP, marker m and the QT q would be uncorrelated (assuming m is not in LD with a second causative polymorphism) and thus the numerator of Equation 7 would be zero implying that:
###end p 59
###begin p 60
###xml 20 24 20 24 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Weir1">[42]</xref>
###xml 25 29 25 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000433-Zaykin1">[44]</xref>
###xml 42 49 42 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000433.s007">Text S1</xref>
###xml 140 141 140 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 243 244 243 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 244 245 244 245 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Based on prior work [42]-[44], we show in Text S1 that the squares of the genotypic correlation coefficient  and LD correlation coefficient r2 are approximately equal if the population is in Hardy-Weinberg equilibrium. Therefore, substituting r2 for  in Equation 8 gives Equation 3.
###end p 60
###begin title 61
Supporting Information
###end title 61
###begin p 62
###xml 175 181 175 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 190 191 190 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 197 198 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 298 304 298 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 306 312 306 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
###xml 387 388 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
QQ plot for association of each GWAS SNP with warfarin dose. SNPs were tested for association with warfarin by regression analysis that adjusted for age, sex, and genotype at VKORC1, CYP2C9*2 and *3, CYP4F2. The QQ plot omits SNPs in loci already known to be associated with warfarin dose (VKORC1, CYP2C9, CYP4F2). The excess of SNPs with small p-values is minor: whereas 65.4 SNPs with p<0.0002 are expected, 70 were observed (1.069 times inflated).
###end p 62
###begin p 63
(0.20 MB PDF)
###end p 63
###begin p 64
Click here for additional data file.
###end p 64
###begin p 65
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 273 275 273 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 292 298 292 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
###xml 324 325 324 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 334 336 334 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;9</sup>
Manhattan plot of GWAS results of testing for association with warfarin-induced over-anticoagulation. Horizontal axis is the genomic position, and vertical axis is minus log of p-value. Red dots above the gray line indicate association of genome-wide significance (p<1.5x10-7) at SNPs in the VKORC1 locus such as rs9923231 (p = 8.9x10-9). However, no other loci achieved genome-wide significance. See main text for more details.
###end p 65
###begin p 66
(0.07 MB PDF)
###end p 66
###begin p 67
Click here for additional data file.
###end p 67
###begin p 68
###xml 88 94 88 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
Multivariate regression results for 40 SNPs followed-up after GWAS. Unlike rs2108622 of CYP4F2, none of these 40 SNPs exhibited statistical significance after correction for multiple testing. See main text for more details.
###end p 68
###begin p 69
(0.03 MB XLS)
###end p 69
###begin p 70
Click here for additional data file.
###end p 70
###begin p 71
Testing for statistical interaction between predictors of warfarin dose. After correcting for the 15 interaction tests, no pair of predictors exhibited statistically significant interaction. Data is for the combined panel of subjects (N = 1641). See main text for more details.
###end p 71
###begin p 72
(0.02 MB XLS)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin p 74
Survival time analysis for incidence of over-anticoagulation within the first 5 weeks of treatment in the whole WARG cohort (N = 1489). See main text for more details.
###end p 74
###begin p 75
(0.02 MB XLS)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin p 77
###xml 182 189 182 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000433-t002">Table 2</xref>
Multiple regression analysis of warfarin dose in WARG replication samples, WARG GWAS plus replication, or Uppsala replication samples. This table shows the same results displayed in Table 2 of the main text except that WARG and Uppsala subjects are separated into different subsets.
###end p 77
###begin p 78
(0.02 MB XLS)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
For populations in Hardy-Weinberg Equilibrium, Linkage Disequilibrium r2 and Genotypic R2 are approximately equal.
###end p 80
###begin p 81
(0.03 MB DOC)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
###xml 33 41 <span type="species:ncbi:9606">patients</span>
We thank all doctors, nurses and patients who participated in this study.
###end p 83
###begin title 84
References
###end title 84
###begin article-title 85
Pharmacogenetics of oral anticoagulants.
###end article-title 85
###begin article-title 86
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.
###end article-title 86
###begin article-title 87
The largest prospective warfarin-treated cohort supports genetic forecasting.
###end article-title 87
###begin article-title 88
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.
###end article-title 88
###begin article-title 89
###xml 7 13 7 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
Common VKORC1 and GGCX polymorphisms associated with warfarin dose.
###end article-title 89
###begin article-title 90
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.
###end article-title 90
###begin article-title 91
The pharmocogenomics of warfarin: closing in on personalized medicine.
###end article-title 91
###begin article-title 92
Association of warfarin dose with genes involved in its action and metabolism.
###end article-title 92
###begin article-title 93
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.
###end article-title 93
###begin article-title 94
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
###end article-title 94
###begin article-title 95
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
###end article-title 95
###begin article-title 96
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP4F2</italic>
CYP4F2 genetic variant alters required warfarin dose.
###end article-title 96
###begin article-title 97
A simple regression method for mapping quantitative trait loci in line crosses using flanking markers.
###end article-title 97
###begin article-title 98
Interval mapping of multiple quantitative trait loci.
###end article-title 98
###begin article-title 99
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 24 29 <span type="species:ncbi:9606">human</span>
Genetic analysis of the human cytochrome P450 CYP2C9 locus.
###end article-title 99
###begin article-title 100
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
###end article-title 100
###begin article-title 101
###xml 26 32 <span type="species:ncbi:9606">humans</span>
Linkage disequilibrium in humans: models and data.
###end article-title 101
###begin article-title 102
Estimating coverage and power for genetic association studies using near-complete variation data.
###end article-title 102
###begin article-title 103
To what extent do scans of non-synonymous SNPs complement denser genome-wide association studies?
###end article-title 103
###begin article-title 104
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VKORC1</italic>
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
###end article-title 104
###begin article-title 105
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.
###end article-title 105
###begin article-title 106
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.
###end article-title 106
###begin article-title 107
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.
###end article-title 107
###begin article-title 108
###xml 57 60 57 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2C9</italic>
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
###end article-title 108
###begin article-title 109
Genetic testing for warfarin therapy initiation.
###end article-title 109
###begin article-title 110
Warfarin Pharmacogenetics.
###end article-title 110
###begin article-title 111
###xml 84 90 84 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data.
###end article-title 111
###begin article-title 112
Incidence and predictors of severe bleeding during warfarin treatment.
###end article-title 112
###begin article-title 113
Internet based clinical trial protocols - as applied to a study of warfarin pharmacogenetics.
###end article-title 113
###begin article-title 114
High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping.
###end article-title 114
###begin article-title 115
Breaking the waves: improved detection of copy number variation from microarray-based comparative genomic hybridization.
###end article-title 115
###begin article-title 116
Circular binary segmentation for the analysis of array-based DNA copy number data.
###end article-title 116
###begin article-title 117
###xml 42 47 <span type="species:ncbi:9606">human</span>
Detection of large-scale variation in the human genome.
###end article-title 117
###begin article-title 118
PLINK: a tool set for whole-genome association and population-based linkage analyses.
###end article-title 118
###begin article-title 119
Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering.
###end article-title 119
###begin article-title 120
###xml 20 25 <span type="species:ncbi:9606">human</span>
A second generation human haplotype map of over 3.1 million SNPs.
###end article-title 120
###begin article-title 121
A robust statistical method for case-control association testing with copy number variation.
###end article-title 121
###begin article-title 122
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 40 53 40 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP3A5, ABCB1</italic>
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.
###end article-title 122
###begin article-title 123
Inferences about linkage disequilibrium.
###end article-title 123
###begin article-title 124
Bounds and normalization of the composite disequilibrium coefficient.
###end article-title 124
###begin p 125
The authors have declared that no competing interests exist.
###end p 125
###begin p 126
This work was supported by the Wellcome Trust. The work was also supported by the Swedish Science Council/Medicine 04496, Swedish Heart and Lung Foundation, the Swedish Society of Medicine, the Swedish Foundation for Strategic Research, the Soderberg, Thureus and Selander Foundations, Nycomed Ltd. of Sweden and the Clinical Research Support (ALF) at Uppsala University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 126

